纳米药物在肝纤维化上的研究进展

Research progress of nano-drugs on liver fibrosis

肝纤维化是慢性肝损伤的一种内在反应,而肝脏中的肝星状细胞在肝纤维化的发生发展中扮演着重要的角色。传统的治疗肝纤维化的药物存在溶解度低、无肝脏靶向性等缺点,目前,随着纳米技术和纳米医学的不断发展,纳米药物以其安全、稳定、缓释、靶向等特性被逐渐运用到针对肝纤维化的开发研究中。近年来,纳米药物在肝纤维化作用机制上的主要关注点是肝星状细胞,以肝星状细胞为靶点,对具有载药特性的无机纳米粒子和有机纳米粒子进行修饰,从而实现对肝纤维化的治疗可能是未来抗肝纤维化研究的主流方向。该文从作用于肝星状细胞的新型纳米药物出发,对近几年在治疗肝纤维化上研究设计的一些纳米药物的分类和应用做一综述。

Hepatic fibrosis is an intrinsic reaction of chronic liver injury,and hepatic stellate cells play an important role in the occurrence and development of hepatic fibrosis.Traditional drugs for the treatment of liver fibrosis have disadvantages such as low solubility and no liver targeting.Nowadays,with the continuous development of nanotechnology and nanomedicine,nano-drugs have been gradually applied to the development and research of liver fibrosis with their characteristics of safety,stability,sustained release and targeting.In recent years the main focus of nano-drugs on the mechanism of liver fibrosis is hepatic stellate cells.It may be the mainstream direction of future anti-liver fibrosis research to modify inorganic and organic nanoparticles with drug-carrying properties to achieve the treatment of liver fibrosis by targeting hepatic stellate cells.This article reviews the classification and application of some new nanomedicines in the treatment of hepatic fibrosis based on the new nanomedicines acting on hepatic stellate cells.